Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343563 | 0.94 | DRD2 (0.50) | BTKEPHX1GAADRD2CA1 | |
| SCHEMBL344546 | 0.94 | DRD2 (0.50) | BTKEPHX1GAADRD2CA1 | |
| SCHEMBL17733738 | 0.94 | DRD2 (0.50) | BTKEPHX1GAADRD2CA1 | |
| SCHEMBL944231 | 0.94 | DRD2 (0.50) | BTKEPHX1GAADRD2CA1 | |
| SCHEMBL941984 | 0.88 | BTK (0.64) | BTKEPHX1GAADRD2CA1 | |
| SCHEMBL25319683 | 0.88 | BTK (0.64) | BTKEPHX1GAADRD2CA1 | |
| SCHEMBL2377443 | 0.88 | BTK (0.64) | BTKEPHX1GAADRD2CA1 | |
| SCHEMBL21027650 | 0.88 | BTK (0.64) | BTKEPHX1GAADRD2CA1 | |
| SCHEMBL25008218 | 0.88 | BTK (0.56) | BTKEPHX1GAADRD2CA1 | |
| SCHEMBL15909157 | 0.88 | BTK (0.64) | BTKEPHX1GAADRD2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055087-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12428404-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240190848-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4313955-A1 | PYRIMIDINE DERIVATIVES USEFUL AS LRRK2 KINASE INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11866423-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117355507-A | Pyrimidine derivatives as LRRK2 kinase inhibitors | 哈利亚治疗公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220324845-A1 | INHIBITORS OF LRRK2 KINASE | Halia Therapeutics, Inc. | 2022-10-13 | — | — | US | disclosed |
| WO-2022204299-A1 | PYRIMIDINE DERIVATIVES USEFUL AS LRRK2 KINASE INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428404-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | BTK 352/4885EPHX1 3742/4885GAA 806/4885 |
| US-11866423-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | BTK 352/4885EPHX1 3742/4885GAA 806/4885 |
| US-20260055087-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PARK7 | BTK 135/4885EPHX1 4661/4885GAA 517/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | BTK 352/4885EPHX1 3742/4885GAA 806/4885 |
| US-20240190848-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | BTK 352/4885EPHX1 3742/4885GAA 806/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | BTK 352/4885EPHX1 3742/4885GAA 806/4885 |
| US-20220324845-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | BTK 358/4885EPHX1 3768/4885GAA 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.